Answers are grounded in this paper and cite their sources.
Pragmatic IHC-based risk score predicts local recurrence in breast cancer, suggesting important prognostic tool.
A pragmatic IHC-based risk score based on routinely available biomarkers stratified local recurrence risk in breast cancer patients treated with BCS and remained stable under sensitivity testing. External validation in larger, multicenter cohorts is warranted.
No takes yet. Share an insight, caveat, or question.
Căluianu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: